> There are countless brilliant founders in biotech who toiled for 5+ years to only find out their drug which had a credible mechanism of action failed phase 2

> There are countless brilliant founders in biotech who toiled for 5+ years to only find out their drug which had a credible mechanism of action failed phase 2 clinicals and now isn't worth a damn. In software, founders of this caliber would have since pivoted and more than likely created a product of some value. That sounds like it's specific to pharma-biotech. In non-pharma biotech there seems to be more freedom to pivot (e.g. this story[0] from a few days ago). [0]: https://news.ycombinator.com/item?id=23749296 https://news.ycombinator.com/item?id=23749296